Athersys, Inc. stock is up 246.17% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 37.5% of the previous 16 December’s closed higher than November.
Athersys, Inc. focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study.